《大行报告》里昂升人保(01339.HK)评级至「跑赢大市」 调整内险股目标价
里昂发表研究报告指,大部分主流寿险商新业务表现自2018年起都未如理想,考虑到短期需求较弱,预期2月至3月份较弱的趋势将持续一段时间,累积的需求仍未浮现,认为寿险改革将成为市场关注重点,当中供应端改革更为重要。
该行指出,最新一轮车险改革将加快市场整合,小型市场参与者陆续被淘汰,预期中国财险(02328.HK)等市场领导者的份额将有所提升。
里昂表示,较看好中国平安(02318.HK)及中国财险,均予「买入」评级,并将人保(01339.HK)的评级由「跑输大市」调升至「跑赢大市」,目标价由2.57元调升至2.95元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.